Wall Street Analysts Believe Haemonetics (HAE) Could Rally 26.58%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 26.6% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Haemonetics (HAE) Upgraded to Strong Buy: What Does It Mean for the Stock?
Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's Why You Should Buy Haemonetics (HAE) Stock Now
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).
Haemonetics' (HAE) Hospital & Plasma Segments, Innovation Aid
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Haemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.
